The capital injection was funded by the internal resources of the group and is for the purpose of meeting the working capital requirements.
The transaction is not expected to have any material impact on the consolidated net tangible assets and earnings per share of the group for FY2021 ending December.
Shares in ValueMax closed flat at 38 cents on April 26.
